Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...

Tyler Sandahl, PharmD, of Mayo Clinic, and Michael Byrne, DO, of Tennessee Oncology, discuss practical advice for bringing ...

A ground breaking study mapping the immune microenvironment in Multiple Myeloma identifies critical immune changes and ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

Biotech HaemaLogiX – which counts former health minister Greg Hunt as a director – is preparing a 2025 ASX listing, as it ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

US FDA accepts for review GSK’s Blenrep combinations for the treatment of relapsed/refractory multiple myeloma: London, UK Tuesday, November 26, 2024, 09:00 Hrs [IST] GSK plc an ...

The study compared CARVYKTI's efficacy and safety against standard-of-care regimens in patients with multiple myeloma.

Growing from a small community led initiative to a major fundraiser, the The Walk of Champions began with a modest $12,000 ...

Patients with relapsed/refractory multiple myeloma could benefit from repeat treatment with drugs their disease has previously been refractory to. Read more.